1. Muntyanu, A, Netchiporouk, E, Gerstein, W, et al. Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. J Cutan Med Surg 2020; 25: 59–76.
Google Scholar | SAGE Journals2. Eggermont, AMM, Chiarion-Sileni, V, Grob, JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16: 522–530.
Google Scholar | Crossref | Medline | ISI3. Hodi, FS, O’Day, SJ, McDermott, DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–723.
Google Scholar | Crossref | Medline | ISI4. Coleman, E, Ko, C, Dai, F, et al. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol 2019; 80: 990–997.
Google Scholar | Crossref | Medline5. Cai, ZR, Lecours, J, Adam, JP, et al. Toxic epidermal necrolysis associated with pembrolizumab. J Oncol Pharm Pract 2019; 26: 1259–1265.
Google Scholar | SAGE Journals6. Zhang, L, Shen, L, Lu, Y, et al. Cancer immunotherapy and toxic epidermal necrolysis. BMJ Support Palliat Care 2020; 10: 314–315.
Google Scholar | Crossref | Medline7. Kumar, R, Bhandari, S. Pembrolizumab induced toxic epidermal necrolysis. Curr Probl Cancer 2020; 44: 100478.
Google Scholar | Crossref | Medline8. Hwang, A, Iskandar, A, Dasanu, CA. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy. J Oncol Pharm Pract 2018; 25: 1520–1522.
Google Scholar | SAGE Journals9. Ellis, SR, Vierra, AT, Millsop, JW, et al. Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J Am Acad Dermatol 2020; 83: 1130–1143.
Google Scholar | Crossref | Medline10. Zavala, S, O’Mahony, M, Joyce, C, et al. How does SCORTEN score? J Burn Care Res 2017; 39: 555–561.
Google Scholar | Crossref11. Naranjo, CA, Busto, U, Sellers, EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245.
Google Scholar | Crossref | Medline | ISI12. de Prost, N, Mekontso-Dessap, A, Valeyrie- Allanore, L, et al. Acute respiratory failure in patients With toxic epidermal necrolysis. Crit Care Med 2014; 42: 118–128.
Google Scholar | Crossref | Medline13. Letko, E, Papaliodis, DN, Papaliodis, GN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005; Apr; 94: 419–436. quiz 436–8, 456.
Google Scholar | Crossref | Medline14. Bastuji-Garin, S, Rzany, B, Stern, RS, et al. Clinical classification of cases of toxic epidermal necrolysis, stevens-johnson syndrome, and erythema Multiforme. Arch Dermatol Res 1993; 129: 92–96.
Google Scholar | Crossref15. Maloney, NJ, Ravi, V, Cheng, K, et al. Stevens-johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review. Int J Dermatol 2020; 59: e183–e188.
Google Scholar | Crossref | Medline16. Goldinger, SM, Stieger, P, Meier, B, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res 2016; 22: 4023–4029.
Google Scholar | Crossref | Medline17. Zhu, J, Chen, G, He, Z, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database. EClinicalMedicine 2021; 37: 100951.
Google Scholar | Crossref | Medline18. Kamińska-Winciorek, G, Cybulska-Stopa, B, Ługowska, I, et al. Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors. Postepy Dermatol Alergol 2019; 36: 382–391.
Google Scholar | Crossref | Medline19. Cheng, L . Current pharmacogenetic perspective on stevens-johnson syndrome and toxic epidermal necrolysis. Front Pharmacol 2021; 12: 588063.
Google Scholar | Crossref | Medline20. Chowell, D, Morris, LGT, Grigg, CM, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 2018; 359: 582–587.
Google Scholar | Crossref | Medline21. Pollack, M, Betof, A, Dearden, H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 2018; 29: 250–255.
Google Scholar | Crossref | Medline